0000000000717224

AUTHOR

Agnija Rasa

showing 7 related works from this author

Adrenal Gland and Gastric Malignant Melanoma without Evidence of Skin Lesion Treated with the Oncolytic Virus Rigvir

2020

Adrenal gland melanoma is an extremely rare diagnosis with less than 20 cases reported. The criteria for diagnosing adrenal gland melanoma include involvement of only one adrenal gland, presence of melanin pigment in the histological examination of the tumor tissue, no primary melanoma tumor in any other organ, and no history of resection of pigmented lesions. However, it is complicated to rule out melanoma of unknown primary origin. Here we report a female patient who at the age of 75 years was admitted to hospital due to suspicion of adrenal and gastric tumor. The largest tumor was found in the adrenal gland, thus leading to the diagnosis of primary adrenal gland melanoma presenting metas…

0301 basic medicinePathologymedicine.medical_specialtyCase ReportDiseaseMetastatic melanomalcsh:RC254-28203 medical and health sciences0302 clinical medicinemedicineOncolytic virotherapyAdrenal glandbusiness.industryMelanomaStomachStandard treatmentlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseAdrenal gland melanomaOncolytic virus030104 developmental biologymedicine.anatomical_structureOncologyTolerability030220 oncology & carcinogenesisSkin lesionbusinessCase Reports in Oncology
researchProduct

A progressive stage IIIB melanoma treated with oncolytic ECHO-7 virus: A case report

2020

Melanoma is an aggressive skin cancer form with a grave prognosis. Current results suggest that oncolytic virus treatment of melanoma has a high therapeutic potential. ECHO-7 (Rigvir) is the first oncolytic virus registered in Latvia. A female patient was diagnosed with stage IIIB melanoma in December 2012, over 9.4 years ago. After the first excision and re-excision, the patient had several recurrences and disease progressions. After the patient had received surgical treatment in 2014, ECHO-7 virus oncolytic virotherapy was started. Since then, the patient has experienced only one more disease progression episode in May 2015 and has been stable for over 60 months. The patient has not rece…

Metastatic melanomaRigvirCase ReportVirus03 medical and health sciences0302 clinical medicinemelanomamedicineVirotherapyoncolytic virus030304 developmental biologylcsh:R5-9200303 health sciencesbusiness.industryMelanomaGeneral MedicineStage iiibmedicine.diseaseOncolytic virus030220 oncology & carcinogenesisCancer researchvirotherapySkin cancerlcsh:Medicine (General)businessECHO-7metastatic melanomaSAGE Open Medical Case Reports
researchProduct

A Case of Stage IV Chromophobe Renal Cell Carcinoma Treated with the Oncolytic ECHO-7 Virus, Rigvir®

2019

Patient: Male, 59 Final Diagnosis: Chromophobe renal cell carcinoma, stage IV Symptoms: Discomfort in the right hypochondrium Medication: Oncolytic virus Rigvir Clinical Procedure: Nephro-adrenalectomy Specialty: Oncology Objective: Unusual or unexpected effect of treatment Background: Renal cell carcinoma is the most commonly diagnosed primary malignant tumor of the kidney in adults, and includes the variant of chromophobe renal cell carcinoma. Despite new targeted therapies that improve progression-free survival (PFS) and overall survival (OS) for early-stage renal cell carcinoma, the 5-year survival for patients with stage IV renal cell carcinoma remains below 10%, and the 50% OS is less…

Malemedicine.medical_specialtymedicine.medical_treatmentChromophobe Renal Cell CarcinomaAdrenal Gland NeoplasmsUrology030204 cardiovascular system & hematologyNephrectomyVirus03 medical and health sciences0302 clinical medicineRenal cell carcinomamedicineCarcinomaHumansCarcinoma Renal CellOncolytic VirotherapyKidneybusiness.industryAdrenalectomyAdrenalectomyArticlesGeneral MedicineMiddle Agedmedicine.diseaseKidney NeoplasmsNephrectomyEnterovirus B HumanOncolytic virusOncolytic Virusesmedicine.anatomical_structure030220 oncology & carcinogenesisbusinessAmerican Journal of Case Reports
researchProduct

Management of a primary malignant melanoma of uterine cervix stage IVA patient with radical surgery and adjuvant oncolytic virus Rigvir® therapy: A c…

2020

Abstract Primary malignant melanoma of the uterine cervix is a rare disease with poor prognosis and high recurrence rate. We used Rigvir® as adjuvant therapy for a stage IVA patient. Tolerability, overall and progression‐free survival are good.

Oncologymedicine.medical_specialtyRigvirmedicine.medical_treatmentlcsh:MedicineCase ReportCase Reports030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineAdjuvant therapymelanomaMedicineRadical surgeryStage (cooking)ECHO-7 virusoncolytic viruslcsh:R5-920business.industryMelanomalcsh:RGeneral Medicinemedicine.diseaseOncolytic virusTolerability030220 oncology & carcinogenesisoncologyECHO‐7 virusbusinesslcsh:Medicine (General)AdjuvantRare diseaseuterine cervixClinical Case Reports
researchProduct

Melanoma Unknown Primary Brain Metastasis Treatment with ECHO-7 Oncolytic Virus Rigvir: A Case Report

2018

Melanoma is considered an aggressive malignancy with a tendency for forming metastasis in the brain. Less than 10% of all melanoma cases present with unknown primary tumor location. This diagnose is yet to be fully understood, because there are only theoretical assumptions about the nature of this disease. Melanoma brain metastases have many severe side effects and unfortunately, any disease related to the brain has limited therapeutic options due to the blood brain barrier. The course of the disease after completing a treatment course, and stopping the treatment, is complicated to predict and is difficult to obtain long-lasting remission. In this report we describe a female patient with un…

0301 basic medicineOncologyNasal cavityCancer Researchmedicine.medical_specialtyCentral nervous systemDiseaseMalignancyblood–brain barrierlcsh:RC254-282Metastasis03 medical and health sciences0302 clinical medicinemelanoma brain metastasisInternal medicinemedicineECHO-7 virusoncolytic virusbusiness.industryMelanomaintranasalmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensOncolytic virus030104 developmental biologymedicine.anatomical_structureOncologymelanoma unknown primary030220 oncology & carcinogenesisbusinessBrain metastasisFrontiers in Oncology
researchProduct

Makrofītu sugu sastāva un sastopamības mainība dabiskos un regulētos upju posmos: Aģes upes piemērs

2015

Bakalaura darba mērķis ir noskaidrot makrofītu sugu sastāva un sastopamības mainību dabiskos un regulētos Aģes upes posmos. Darbā veikti upes veģetācijas pētījumi 10 Aģes posmos, no kuriem 5 posmi ir regulēti, bet 5 dabiski; novērtēta upes posmu ekoloģiskā kvalitāte, izmantojot trofijas un sugu daudzveidības indeksus, kā arī noteikti makrofītu augšanu ietekmējošie vides faktori. Iegūtie rezultāti parāda, ka Aģes regulētajos posmos ūdens ekoloģiskā kvalitāte un makrofītu sugu daudzveidība ir zemāka salīdzinājumā ar upes dabiskajiem posmiem.

trofijas indeksiVides zinātnedabiski un regulēti upju posmisugu daudzveidības indeksiAģemakrofīti
researchProduct

Aģes upes lejteces ekoloģiskā kvalitāte

2017

Maģistra darba mērķis ir noskaidrot Aģes upes lejteces ekoloģisko kvalitāti. Darba ietvaros veikti upes veģetācijas un ķīmiskā sastāva pētījumi 6 Aģes upes posmos, kuri ietilpst riska ūdensobjektā G261SP „Mazupīte – grīva”; novērtēta posmu ekoloģiskā kvalitāte, izmantojot trofijas indeksus un ūdens ķīmisko analīžu rādītājus. Noteikti arī makrofītu augšanu ietekmējošie vides faktori. Iegūtie rezultāti parāda, ka pēc makrofītu trofijas indeksiem Aģes upes lejteces ekoloģiskā kvalitāte ir labāka nekā pēc ķīmiskā stāvokļa. Kopumā lejteces ekoloģiskā kvalitāte ir slikta.

trofijas indeksiVides zinātnevides faktoriekoloģiskā kvalitātevidēji liela upemakrofīti
researchProduct